TopMarketGainers
Long

Tandem Diabetes Care Inc Has Huge growth potential

NASDAQ:TNDM   TANDEM DIABETES CARE INC
Jim Cramer spoke with Kim Blickenstaff, executive chairman at Tandem Diabetes Care ( TNDM ) , which posted strong earnings last week but quickly reversed, Blickenstaff blamed the sudden reversal in their shares on global uncertainty. He said Tandem has no business in China and is in "acceleration mode."
Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem. The market potential is even greater worldwide, especially in Europe as the condition continues to become a epidemic.
The chart remains bullish but maybe more confirmation required before placing a trade.

TANDEM DIABETES CARE INC .
Tandem Diabetes Care , Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

AVERAGE ANALYSTS PRICE TARGET $82
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 7%
Do you want to GAIN an Edge on Wall Street?

1) Sign Up for our Free Email Newsletter @
http://www.TopMarketGainers.com

2) Sign Up for our Free Text Message Notifications
by Texting 'GAINS' to 67076.

(*It's FREE, however Msg&Data rates may apply
It is a very interesting one to watch - although I see a potential for big shake-up surrounding insulin pricing. The USA allows for pharma to charge absurd prices for insulin; something that doesn't happen in other places (like neighboring Canada). This is something that seems to be on the President's agenda as of late, as he has made recent statements about problems with insulin pricing. I do not see how the USA can continue allowing these huge prices for common drugs like insulin. Whether or not politicians will ever act to change the laws around collective bargaining for drug prices etc is another story - but it will be interesting to follow! If changes ever did come, Tandem may be protected, as their product is primarily an insulin delivery system, opposed to the actual insulin.
Reply
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out